Company Phytopharm plc London S.E.

Equities

GB0006869720

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Sector Other Biotechnology & Medical Research

Inactive Instrument

End-of-day quote London S.E. Other stock markets
- ^GBX	-

19/06	Ixico Bags Over GBP1 Million Contract for Parkinsonian Disorder Study	MT
19/06	AIM WINNERS & LOSERS: Ixico and Light Science Technologies win deal	AN

IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.

GBP in Million	2022	Weight	2023	Weight	Delta
Clinical Trials Services 100.0 %	9	100.0 %	7	100.0 %	-22.89%

GBP in Million	2022	Weight	2023	Weight	Delta
United States 45.8 %	3	31.4 %	3	45.8 %	+12.62%
United Kingdom 14.3 %	2	23.8 %	1	14.3 %	-53.72%
Netherlands 12.9 %	0	5.0 %	1	12.9 %	+97.71%
Switzerland 12.2 %	2	24.0 %	1	12.2 %	-60.71%
Ireland 10.3 %	1	8.4 %	1	10.3 %	-4.83%
Europe 4.4 %	1	7.4 %	0	4.4 %	-54.08%

Managers	Title	Age	Since
Giulio Cerroni CEO	Chief Executive Officer	63	06/17/06
Grant Robert Nash DFI	Director of Finance/CFO	47	31/19/31
Charles Spicer CHM	Chairman	59	14/13/14
Romina Oxborough COO	Chief Operating Officer	-	-
Robin Wolz CTO	Chief Tech/Sci/R&D Officer	-	01/21/01
Michelle Lax CTO	Chief Tech/Sci/R&D Officer	45	01/12/01

Members of the board	Title	Age	Since
Charles Spicer CHM	Chairman	59	14/13/14
Mark Robert Warne BRD	Director/Board Member	49	16/16/16
Dipti Amin BRD	Director/Board Member	60	05/23/05
Giulio Cerroni CEO	Chief Executive Officer	63	06/17/06
Grant Robert Nash DFI	Director of Finance/CFO	47	31/19/31
Katherine Jane Rogers BRD	Director/Board Member	57	21/22/21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	48,351,373	24,741,986 ( 51.17 %)	0	51.17 %

Name	Equities	%	Valuation
BGF Investment Management Ltd. 18.46 %	8,924,000	18.46 %	803 785 p
Octopus Investments Ltd. 13.25 %	6,408,400	13.25 %	577 205 p
Gresham House Asset Management Ltd. 10.69 %	5,166,972	10.69 %	465 389 p
Canaccord Genuity Wealth Ltd. 9.685 %	4,683,071	9.685 %	421 804 p
Amati Global Investors Ltd. (Venture Capital) 9.612 %	4,647,697	9.612 %	418 618 p
CFE (UK) Ltd. 7.978 %	3,857,566	7.978 %	347 451 p
Hargreaves Lansdown Asset Management Ltd. 5.499 %	2,659,000	5.499 %	239 496 p
City Asset Management Plc 2.953 %	1,427,860	2.953 %	128 607 p
Hardsteel Ltd. 1.752 %	847,000	1.752 %	76 289 p
Marcus Sarner 1.295 %	626,000	1.295 %	56 384 p

Ixico Plc

Griffin Court 15 Long Lane

EC1A 9PN, London

+44 20 3763 7499

http://www.ixico.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+26.29%	46.56B
LONZA GROUP AG	+44.59%	41.67B
IQVIA HOLDINGS INC.	-0.46%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+34.54%	32.4B
ICON PUBLIC LIMITED COMPANY	+21.04%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.47%	14.52B
MEDPACE HOLDINGS, INC.	+47.01%	13.74B
BIO-TECHNE CORPORATION	+1.44%	12.17B

Other Biotechnology & Medical Research